It's about time to write off high-growth tech stocks, Goldman warned, saying software carries the highest multiples since the tech bubble.Marketsread more
Iran will surpass the internationally agreed levels of its low-enriched uranium levels in 10 days, the country's atomic energy body said Monday.Politicsread more
Boeing said the airline industry will need 44,040 new commercial airplanes by 2038. The market value of those planes would reach $6.8 trillion, up from $6.49 trillion...Airlinesread more
Sotheby's announces it has signed an agreement to be acquired by BidFair USA, a venture owned by art collector Patrick Drahi.Marketsread more
Apple is reportedly building three new iPhones for 2020, including two with 5G. It may also slightly change the screen sizes of the new iPhones.Technologyread more
Overall, extortion by email is growing significantly, according to the FBI's Internet Crime Compliant Center (IC3). Last year, these complaints rose 242% to 51,146 reported...Technologyread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
Target's nationwide cash register meltdown over the weekend created more than $16 million in buzz on the internet from news reports and other social media mentions, according...Retailread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
The top court scrapped a ruling from the Oregon Court of Appeals in favor of the same-sex couple. The owners of the bakery, which refused the make the cake due to religious...Politicsread more
Boeing reached a deal with British Airways to provide parts for some of its plane's made by rival manufacturer Airbus, part of Boeing's push to grow its services business.Airlinesread more
Now is the time to buy MedTech names because positive fundamentals and a favorable regulatory backdrop will continue to drive gains, Barclays analyst Kristen Stewart wrote in a note to clients on Tuesday.
Stewart initiated coverage on the sector with a "positive view," noting that "innovation trends continue to improve thanks in part to a more favorable FDA environment" and that "the industry's structure (e.g. oligopolies) is favorable and conducive to profitable growth."
Her top picks in the space are Abbott Labs, Boston Scientific, Stryker, and Medtronic, all of which she initiated as "overweight." On the flip side, she rated Baxter, Edwards Lifesciences, and Zimmer Biomet "underweight" due to "greater earnings risk."
Stewart is bullish on Abbott Labs specifically because she believes the company's product pipeline and "favorable mix of businesses" can drive the stock to $80 -- a 12.76% jump from Tuesday's closing price of $70.95.
Some investors, however, believe there's better value elsewhere in the sector given Abbott's 24.3% rise year-to-date. Stephanie Link, managing director at Nuveen which has $970 billion in assets under management, recently sold her position in Abbott and used the profits to buy competitor Zimmer Biomet.
"I think this new management team at Zimmer has a lot of optionality," she said on Tuesday's "Halftime Report." "I think they're going to make some asset sales. I think they're going to fix the base business - they're already in the process - and this CEO is so highly regarded."
Zimmer is cheaper than Abbott at 16.2X forward earnings compared to 22.4X, and the stock is only up 5.8% year-to-date, through Tuesday's close, compared to Abbott's 24.3% gain.
Barclays' Stewart has an underweight rating on Zimmer since she believes the "transformation [is] likely to take significant time." While Link agrees that it's going to "take time to turn around," she believes the relative underperformance is an attractive entry point to buy the stock. "I just find more value in Zimmer. I'm not saying I don't like Abbott, I just think it [Abbott] has run its course," she said.
Virtus Investment Partners' Joe Terranova, on the other hand, owns Abbott Labs and is sticking with it since he believes the company's foothold in emerging markets will lead to continued gains.
"I still think Abbott is the place to be," he said on Tuesday's "Halftime Report." "I like the emerging market story. I like the pediatric nutrition business both in Latin America and greater China...I believe in the emerging consumer. I believe they're going to want this type of health care, and this is as good of a diversified health care company as you're going to find," he continued.
In medical devices Terranova also likes PerkinElmer. He had previously owned the stock, but sold his position after it hit an all-time high of $98.33 on October 1. Since then, however, it's fallen more than 9%. So Terranova took advantage of the pullback and bought the stock again on Tuesday since he believes it's a "great quality name."
Health care led all sectors in Q3 -- posting a 14.04% gain for its best quarterly performance since Q1 2013 -- as investors rotated away from some of the high-flying tech names and into more defensive plays. And with an increasing number of Street watchers warning this bull market could be in its final stages, Terranova believes the health care sector is a good bet for investors going forward.
"I think from a quality standpoint when you're looking at sustainable earnings this is definitely a sector [health care] that where we are in the cycle you want to have exposure to. And I don't think investors are nearly as exposed as they should be," he said.